



MAPT FTD is **The Missing Population** in Tau Drug Development.


22 years of Tau-targeting drug development



Tau-targeting trials



Indications across 74 trials



Out of 33 Tau-targeting drugs tested across 74 clinical trials over 22 years, **only 1 trial included MAPT mutation carriers**

As of 2026 there are **0 Therapeutic Trials** open to MAPT carriers

Cure MAPT FTD is ready to enroll our families — we are genetically confirmed, biomarker-tracked in GENFI & ALLFTD cohorts, and committed to participating in Tau-targeting research.

55 family kindreds **10** countries **500+** individuals ready to enroll

Why include MAPT families?



Pure Tau pathology

The only population with Tau pathology and no co-pathology.



Tau is cause, not consequence

Pathogenic MAPT variants act directly on the drug's target.



Predictable trajectory

Progression tracked via GENFI/ ALLFTD natural history cohorts.



Identifiable presymptomatically

A genetic test confirms carriers years before symptom onset.



Validated biomarkers

CSF & blood-based Tau, plasma NfL, and Tau PET — all validated in MAPT carriers.



Regulatory precedent

FDA approved tofersen for SOD1-ALS (~330 patients) on a biomarker endpoint.